158 related articles for article (PubMed ID: 31551920)
21. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.
Adachi H; Waza M; Tokui K; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
J Neurosci; 2007 May; 27(19):5115-26. PubMed ID: 17494697
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).
Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
Cell Tissue Res; 2012 Jul; 349(1):313-20. PubMed ID: 22476656
[TBL] [Abstract][Full Text] [Related]
23. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy.
Sahashi K; Katsuno M; Hung G; Adachi H; Kondo N; Nakatsuji H; Tohnai G; Iida M; Bennett CF; Sobue G
Hum Mol Genet; 2015 Nov; 24(21):5985-94. PubMed ID: 26231218
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA).
Suzuki K; Kastuno M; Banno H; Sobue G
Neuropathology; 2009 Aug; 29(4):509-16. PubMed ID: 19486304
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
Adachi H; Waza M; Katsuno M; Tanaka F; Doyu M; Sobue G
Neuropathol Appl Neurobiol; 2007 Apr; 33(2):135-51. PubMed ID: 17359355
[TBL] [Abstract][Full Text] [Related]
26. Troponin T in spinal and bulbar muscular atrophy (SBMA).
Musso G; Blasi L; Mion MM; Fortuna A; Sabbatini D; Zaninotto M; Bello L; Pegoraro E; Basso D; Plebani M; Sorarù G
J Neurol Sci; 2024 Jan; 456():122816. PubMed ID: 38071852
[TBL] [Abstract][Full Text] [Related]
27. [SBMA: a rare disease but a classic ALS mimic syndrome].
Pradat PF
Presse Med; 2014 May; 43(5):580-6. PubMed ID: 24785145
[TBL] [Abstract][Full Text] [Related]
28. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
Sobue G
Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
[TBL] [Abstract][Full Text] [Related]
29. Discrimination of spinal and bulbar muscular atrophy from amyotrophic lateral sclerosis using sensory nerve action potentials.
Hama T; Hirayama M; Hara T; Nakamura T; Atsuta N; Banno H; Suzuki K; Katsuno M; Tanaka F; Sobue G
Muscle Nerve; 2012 Feb; 45(2):169-74. PubMed ID: 22246870
[TBL] [Abstract][Full Text] [Related]
30. Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy.
Butler R; Leigh PN; McPhaul MJ; Gallo JM
Hum Mol Genet; 1998 Jan; 7(1):121-7. PubMed ID: 9384612
[TBL] [Abstract][Full Text] [Related]
31. Myoglobin: a new biomarker for spinal and bulbar muscular atrophy?
Guo H; Lu M; Ma Y; Liu X
Int J Neurosci; 2021 Dec; 131(12):1209-1214. PubMed ID: 32729750
[TBL] [Abstract][Full Text] [Related]
32. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.
Katsuno M; Adachi H; Tanaka F; Sobue G
J Mol Med (Berl); 2004 May; 82(5):298-307. PubMed ID: 15133611
[TBL] [Abstract][Full Text] [Related]
33. Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy.
Yamada S; Hashizume A; Hijikata Y; Inagaki T; Suzuki K; Kondo N; Kawai K; Noda S; Nakanishi H; Banno H; Hirakawa A; Koike H; Halievski K; Jordan CL; Katsuno M; Sobue G
PLoS One; 2016; 11(12):e0168846. PubMed ID: 28005993
[TBL] [Abstract][Full Text] [Related]
34. Spinal and bulbar muscular atrophy.
Lieberman AP
Handb Clin Neurol; 2018; 148():625-632. PubMed ID: 29478604
[TBL] [Abstract][Full Text] [Related]
35. Defects in Neuromuscular Transmission May Underlie Motor Dysfunction in Spinal and Bulbar Muscular Atrophy.
Xu Y; Halievski K; Henley C; Atchison WD; Katsuno M; Adachi H; Sobue G; Breedlove SM; Jordan CL
J Neurosci; 2016 May; 36(18):5094-106. PubMed ID: 27147661
[TBL] [Abstract][Full Text] [Related]
36. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity.
Klickovic U; Zampedri L; Sinclair CDJ; Wastling SJ; Trimmel K; Howard RS; Malaspina A; Sharma N; Sidle K; Emira A; Shah S; Yousry TA; Hanna MG; Greensmith L; Morrow JM; Thornton JS; Fratta P
Neurology; 2019 Aug; 93(9):e895-e907. PubMed ID: 31391248
[TBL] [Abstract][Full Text] [Related]
37. A mouse model of spinal and bulbar muscular atrophy.
McManamny P; Chy HS; Finkelstein DI; Craythorn RG; Crack PJ; Kola I; Cheema SS; Horne MK; Wreford NG; O'Bryan MK; De Kretser DM; Morrison JR
Hum Mol Genet; 2002 Sep; 11(18):2103-11. PubMed ID: 12189162
[TBL] [Abstract][Full Text] [Related]
38. Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice.
Perera ND; Sheean RK; Crouch PJ; White AR; Horne MK; Turner BJ
Hum Mol Genet; 2016 Sep; 25(18):4080-4093. PubMed ID: 27466204
[TBL] [Abstract][Full Text] [Related]
39. [Molecular-targeted therapy for motor neuron disease].
Banno H; Katsuno M; Suzuki K; Iguchi Y; Adachi H; Tanaka F; Sobue G
Brain Nerve; 2009 Aug; 61(8):891-900. PubMed ID: 19697878
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy.
Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
Arch Neurol; 2012 Apr; 69(4):436-40. PubMed ID: 22158719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
